Author
IMAMURA, FUMIAKI - University Of Cambridge | |
FRETTS, AMANDA - University Of Washington | |
MARKLUND, MATTI - Uppsala University | |
ARDISSON KORAT, ANDRES - Harvard School Of Public Health | |
YANG, WEI - University Of Eastern Finland | |
LANKINEN, MARIA - University Of Eastern Finland | |
QURESHI, WAQAS - Wake Forest School Of Medicine | |
HELMER, CATHERINE - University Of Bordeaux | |
CHEN, TZU - Children'S Nutrition Research Center (CNRC) | |
WONG, KERRY - Cancer Council Victoria | |
BASSETT, JULIE - Cancer Council Victoria | |
MURPHY, RACHEL - University Of British Columbia | |
TINTLE, NATHAN - Dordt College | |
YU, CHARYU - University Of Washington | |
BROUWER, INGEBORG - Vrije University | |
CHIEN, KUO - University Of Eastern Finland | |
FRAZIER-WOOD, ALEXIS - Children'S Nutrition Research Center (CNRC) | |
DEL GOBBO, LIANA - Stanford University School Of Medicine | |
DJOUSSE, LUC - Brigham & Women'S Hospital | |
GELEIJNSE, JOHANNA - Wageningen University | |
GILES, GRAHAM - Cancer Council Victoria | |
DE GOEDE, JANETTE - Wageningen University | |
GUDNASON, VILMUNDUR - Icelandic Heart Association | |
HARRIS, WILLIAM - University Of South Dakota | |
HODGE, ALLISON - Cancer Council Victoria | |
HU, FRANK - Harvard School Of Public Health | |
KOULMAN, ALBERT - University Of Cambridge | |
LAAKSO, MARKKU - University Of Kuopio | |
LIND, LARS - Uppsala University | |
LIN, HUNG - National Taiwan University | |
MCKNIGHT, BARBARA - University Of Washington | |
RAJAOBELINA, KALINA - University Of Bordeaux | |
RISERUS, ULF - Uppsala University | |
ROBINSON, JENNIFER - University Of Iowa | |
SAMIERI, CECILIA - University Of Bordeaux | |
SISCOVICK, DAVID - New York Academy Of Medicine | |
SOEDAMAH-MUTHU, SABITA - Wageningen University | |
SOTOODEHNIA, NONA - University Of Washington | |
SUN, QI - Harvard School Of Public Health | |
TSAI, MICHAEL - University Of Minnesota | |
UUSITUPA, MATTI - University Of Eastern Finland | |
WAGENKNECHT, LYNNE - Wake Forest School Of Medicine | |
WAREHAM, NICK - University Of Cambridge | |
WU, JASON - University Of New South Wales | |
MICHA, RENATA - Friedman School At Tufts | |
FOROUHI, NITA - University Of Cambridge | |
LEMAITRE, ROZENN - University Of Washington | |
MOZZAFFARIAN, DARIUSH - Friedman School At Tufts |
Submitted to: PLoS Medicine
Publication Type: Peer Reviewed Journal Publication Acceptance Date: 9/7/2018 Publication Date: 10/10/2018 Citation: Imamura, F., Fretts, A., Marklund, M., Ardisson Korat, A.V., Yang, W.S., Lankinen, M., Qureshi, W., Helmer, C., Chen, T.A., Wong, K., Bassett, J.K., Murphy, R., Tintle, N., Yu, C.I., Brouwer, I.A., Chien, K.L., Frazier-Wood, A.C., Del Gobbo, L.C., Djousse, L., Geleijnse, J.M., Giles, G.G., De Goede, J., Gudnason, V., Harris, W.S., Hodge, A., Hu, F., Koulman, A., Laakso, M., Lind, L., Lin, H.J., McKnight, B., Rajaobelina, K., Riserus, U., Robinson, J.G., Samieri, C., Siscovick, D.S., Soedamah-Muthu, S.S., Sotoodehnia, N., Sun, Q., Tsai, M.Y., Uusitupa, M., Wagenknecht, L.E., Wareham, N.J., Wu, J.J., Micha, R., Forouhi, N.G., Lemaitre, R.N., Mozzaffarian, D. 2018. Fatty acid biomarkers of dairy fat consumption and incidence of type 2 diabetes: A pooled analysis of prospective cohort studies. PLoS Medicine. 15(10):e1002670. https://doi.org/10.1371/journal.pmed.1002670. DOI: https://doi.org/10.1371/journal.pmed.1002670 Interpretive Summary: National and international guidelines recommend the consumption of dairy products. Additionally, in high income countries recommendations further specify the consumption of fat-reduced dairy products instead of whole-fat products. However, these recommendations are based on the overall desire to reduce fat intake at the population level, instead of the health effects of dairy fat. However, total consumption of dairy products has been related with a lower number of newly diagnosed cases of type 2 diabetes (T2D) suggesting that reducing dairy (even of the high-fat variety) may not be beneficial for health. Typically, studies looking at the effects of dairy consumption on T2D use self-reported questionnaires, which can introduce reporting bias and thus not provide a good assessment. As a result, few studies have used biomarkers (biological markers or things found in the body) to examine the relationship between specific biomarkers reflecting dairy fat consumption and new cases of T2D. To address this limitation, we conducted a study with 16 groups from around the world (7 from the United States, 7 from Europe, 1 from Australia, 1 from Taiwan). Specifically, we developed a strategy for combining all studies to maximize statistical power, generalizability of the study findings, standardize the statistical analysis procedures and methods. We used 3 biomarkers of dairy intake (3 types of fatty acids) for the study analyses. Data from 63,682 individuals with no T2D at the beginning of each study and 15,180 new T2D cases at follow-up (average duration of follow-up assessments across the studies was 9 years) were analyzed. Overall, we found that each biomarker of dairy intake was related to lower risk for developing T2D independent from age, sex, race/ethnicity, socioeconomic status, physical activity, and body mass index (BMI). The results of this study are significant because they provide the strongest evidence to date for relationship of dairy intake to protection from T2D. This information may be useful to clinicians who have to counsel individuals at risk of T2D on the best dietary strategies to adopt, and those who have to make policy decisions on dietary guidelines. Technical Abstract: We aimed to investigate prospective associations of circulating or adipose tissue odd-chain fatty acids 15:0 and 17:0 and trans-palmitoleic acid, t16:1n-7, as potential biomarkers of dairy fat intake, with incident type 2 diabetes (T2D). Sixteen prospective cohorts from 12 countries (7 from the United States, 7 from Europe, 1 from Australia, 1 from Taiwan) performed new harmonized individual-level analysis for the prospective associations according to a standardized plan. In total, 63,682 participants with a broad range of baseline ages and BMIs and 15,180 incident cases of T2D over the average of nine years of follow-up were evaluated. Study-specific results were pooled using inverse variance weighted meta-analysis. Prespecified interactions by age, sex, body-mass index (BMI), and race/ethnicity were explored in each cohort and meta-analysed. Potential heterogeneity by cohort-specific characteristics (regions, lipid compartments used for fatty acid assays) was assessed with meta-regression. After adjustment for potential confounders including measures of adiposity (BMI, waist circumference) and lipogenesis (levels of palmitate, triglycerides), higher levels of 15:0, 17:0, and t16:1n-7 were associated with lower incidence of T2D. In the most adjusted model, the hazard ratio (95% CI) for incident T2D per cohort-specific 10th to 90th percentile range of 15:0 was 0.80 (0.73-0.87); of 17:0, 0.65 (0.59-0.72); of t16:1n7, 0.82 (0.70-0.96); and of their sum, 0.71 (0.63-0.79). In exploratory analyses, similar associations for 15:0, 17:0, and the sum of all three fatty acids was present in both genders but stronger in women than in men (p interaction<0.001). While studying associations with biomarkers has several advantages, as limitations, the biomarkers do not distinguish between different food sources of dairy fat (e.g., cheese, yogurt, milk); and residual confounding by unmeasured or imprecisely measured confounders may exist. In a large meta-analysis that pooled the findings from sixteen prospective cohort studies, higher levels of 15:0, 17:0 and t16:1n-7 were associated with a lower risk of T2D. |